COMMUNIQUÉS West-GlobeNewswire

Informations relatives au nombre total de droits de vote et d’actions composant le capital
08/07/2026
Nantes, le 8 juillet 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), une société de [...]
SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1)
08/07/2026
Approximately $40 million in cash and more than $15 million in short-term investment assets as of June 30, 2026 1 Estimated net asset value of approximately $60 million and no debt outstanding as of June 30, 2026¹ [...]
GENFIT : Bilan semestriel du contrat de liquidité contracté avec le Crédit Industriel et Commercial
08/07/2026
Lille (France), Cambridge (Massachusetts, États-Unis), Zurich (Suisse), le 08 juillet 2026 – GENFIT (Euronext : GNFT) , société biopharmaceutique engagée dans l’amélioration de la vie des patients atteints de maladies [...]
Sienna Announces Second Quarter 2026 Results Release Date and Conference Call
08/07/2026
MARKHAM, Ontario, July 08, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2026 second quarter results after market close on Tuesday, [...]
Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
08/07/2026
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2026 - GENFIT (Euronext: GNFT) , a biopharmaceutical company dedicated to improving the lives of patients with rare and life- [...]
Half-Year Report on Liquidity Contract with Invest Securities
08/07/2026
NANTES, France, July 8, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) – Under the liquidity contract entrusted by OSE Immunotherapeutics to Invest Securities, the following resources [...]
Bilan semestriel du contrat de liquidité avec Invest Securities
08/07/2026
NANTES, France, le 8 juillet 2026, 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) – Au titre du contrat de liquidité confié par OSE Immunotherapeutics à Invest Securities, les moyens suivants [...]
ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)
08/07/2026
Granted claims cover the use of vafidemstat for treating non-aggressive symptoms of BPD U.S. patent to expire in March 2043, including 1,095 days of Patent Term Adjustment Notice of allowance also received in a [...]
SBC Medical Launches Japan's First Specialized Men's Beard Hair Removal Clinic, Introducing a Scalable, Capital-Efficient Growth Platform
08/07/2026
Opening of SBC MEN'S FLASH CLINIC in Ikebukuro, Tokyo, on August 6, 2026 IRVINE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a [...]
NOMAD Increases Voyager Fleet Energy Storage by up to 56%, Bringing Eagle and Falcon to 2.025 MWh
08/07/2026
Boca Raton, Fla., July 08, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”) (Nasdaq: NMAD), through its wholly owned subsidiary, Nomad Transportable Power Systems Inc., today announced the [...]
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
08/07/2026
License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease Agreement builds on [...]
SRX Global Declares One-Time Cash Dividend
08/07/2026
Company delivering $1 million in aggregate to shareholders via cash dividend payment from profits related to investment in SpaceX and hedging strategies NORTH PALM BEACH, Fla., July 08, 2026 (GLOBE NEWSWIRE) -- SRX [...]
Polomar Health Services Strengthens Board Leadership to Support Standalone Growth Strategy
08/07/2026
Hornig Appointed Executive Chairman; Caruolo Appointed Lead Independent Director PALM HARBOR, Fla., July 08, 2026 (GLOBE NEWSWIRE) -- Polomar Health Services, Inc. (OTCQB: PMHS) (“Polomar” or the “Company”), a [...]
International Gastroenterology Expert Working Group Publishes Consensus Framework for Improved Classification of Gastric Function in Patients with Chronic Stomach Conditions
08/07/2026
Neurogastroenterology & Motility paper describes the Auckland Classification, which is designed to bring clinical clarity to the hundreds of millions of patients worldwide The Auckland Classification, developed with [...]
Families Report Positive Outcomes From Fully Virtual, BCBA-Delivered, Focused Autism Support Program
08/07/2026
Study finds that fully virtual applied behavior analysis therapy conducted by BCBA clinicians at AnswersNow for autism support is feasible, well received by caregivers, and linked to positive outcomes for children and [...]
Spectral AI Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepView® System for Burn Indication
08/07/2026
Industry Veteran Brings Two Decades of Experience Driving Growth Through New Product Launches, Training and Education DALLAS, July 08, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “ [...]
Cannabix Technologies and Omega Laboratories Announce Breath-Based DOT-Like Drug Testing Panel for Recent-Use Detection
08/07/2026
Expanded breath-testing capability enables recent-use detection across a panel modeled after the DOT federally mandated urine drug test panel. VANCOUVER, British Columbia, July 08, 2026 (GLOBE NEWSWIRE) -- Cannabix [...]
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
08/07/2026
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results [...]
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
08/07/2026
FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027 Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label [...]

Pages